Prophylactic Human Papillomavirus Vaccination: A Breakthrough in Primary Cervical Cancer Prevention

Francisco A Garcia, Debbie Saslow

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent carcinogenesis. The identification of this obligate viral etiology, in addition to a vast knowledge about the HPV viral life cycle and resultant host response, has led to a vaccine approach to cervical cancer prevention. The use of prophylactic cancer vaccine as primary prevention holds the most promise for long-term cancer prevention but raises some important and as yet unanswered questions that are addressed in this article.

Original languageEnglish (US)
Pages (from-to)761-781
Number of pages21
JournalObstetrics and Gynecology Clinics of North America
Volume34
Issue number4
DOIs
StatePublished - Dec 2007

Fingerprint

Papillomavirus Infections
Uterine Cervical Neoplasms
Vaccination
Cancer Vaccines
Primary Prevention
Life Cycle Stages
Carcinogenesis
Vaccines
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Prophylactic Human Papillomavirus Vaccination : A Breakthrough in Primary Cervical Cancer Prevention. / Garcia, Francisco A; Saslow, Debbie.

In: Obstetrics and Gynecology Clinics of North America, Vol. 34, No. 4, 12.2007, p. 761-781.

Research output: Contribution to journalArticle

@article{f3b0f614074249d386c4ee4337df188f,
title = "Prophylactic Human Papillomavirus Vaccination: A Breakthrough in Primary Cervical Cancer Prevention",
abstract = "Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent carcinogenesis. The identification of this obligate viral etiology, in addition to a vast knowledge about the HPV viral life cycle and resultant host response, has led to a vaccine approach to cervical cancer prevention. The use of prophylactic cancer vaccine as primary prevention holds the most promise for long-term cancer prevention but raises some important and as yet unanswered questions that are addressed in this article.",
author = "Garcia, {Francisco A} and Debbie Saslow",
year = "2007",
month = "12",
doi = "10.1016/j.ogc.2007.09.007",
language = "English (US)",
volume = "34",
pages = "761--781",
journal = "Obstetrics and Gynecology Clinics of North America",
issn = "0889-8545",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Prophylactic Human Papillomavirus Vaccination

T2 - A Breakthrough in Primary Cervical Cancer Prevention

AU - Garcia, Francisco A

AU - Saslow, Debbie

PY - 2007/12

Y1 - 2007/12

N2 - Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent carcinogenesis. The identification of this obligate viral etiology, in addition to a vast knowledge about the HPV viral life cycle and resultant host response, has led to a vaccine approach to cervical cancer prevention. The use of prophylactic cancer vaccine as primary prevention holds the most promise for long-term cancer prevention but raises some important and as yet unanswered questions that are addressed in this article.

AB - Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent carcinogenesis. The identification of this obligate viral etiology, in addition to a vast knowledge about the HPV viral life cycle and resultant host response, has led to a vaccine approach to cervical cancer prevention. The use of prophylactic cancer vaccine as primary prevention holds the most promise for long-term cancer prevention but raises some important and as yet unanswered questions that are addressed in this article.

UR - http://www.scopus.com/inward/record.url?scp=36549029868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549029868&partnerID=8YFLogxK

U2 - 10.1016/j.ogc.2007.09.007

DO - 10.1016/j.ogc.2007.09.007

M3 - Article

C2 - 18061868

AN - SCOPUS:36549029868

VL - 34

SP - 761

EP - 781

JO - Obstetrics and Gynecology Clinics of North America

JF - Obstetrics and Gynecology Clinics of North America

SN - 0889-8545

IS - 4

ER -